ReviewAnnals of translational medicine2020
Surveillance for acute cellular rejection after lung transplantation.
Review in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- International Society for Heart and Lung Transplantation Scientific Statement on pulmonary antibody-mediated rejection and proposed graft, antibody, and pathology (GAP) definition.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2026Guideline
- Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation.Frontiers in immunology · 2023Pooled it
- Serendipity on surveillance: an unusual transbronchial biopsy finding in a lung transplant recipient.Clinical transplantation and research · 2026Article
- When BAL meets CT scan: enhancing noninvasive diagnosis of acute cellular rejection after lung transplantation.BMC pulmonary medicine · 2026Article
- Exploring acute cellular rejection in lung transplantation: insights from donor-derived cell-free DNA analysis.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2026Article
- Development and validation of a bronchoalveolar lavage genomic classifier for acute cellular rejection.EBioMedicine · 2025Article
- High-dimensional flow cytometry reveals lymphocyte subset populations predictive of chronic lung allograft dysfunction.Clinical & translational immunology · 2025Article
- Efficacy of transbronchial biopsy and frequency of pneumothorax in lung transplant recipients: single center experience.BMC pulmonary medicine · 2024Article
- Efficacy of surveillance bronchoscopyERJ open research · 2024Review
- Tissue-resident memory T cells and lung immunopathology.Immunological reviews · 2023Review
- The role of confocal laser endomicroscopy in pulmonary medicine.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Single center study investigating the clinical association of donor-derived cell-free DNA with acute outcomes in lung transplantation.Frontiers in transplantation · 2023Article
- Transbronchial Cryobiopsy Compared to Forceps Biopsy for Diagnosis of Acute Cellular Rejection in Lung Transplants: Analysis of 63 Consecutive Procedures.Life (Basel, Switzerland) · 2022Article
- The Roles of Tissue-Resident Memory T Cells in Lung Diseases.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute cellular rejection (ACR) is a common complication following lung transplantation (LTx), affecting almost a third of recipients in the first year. Established, comprehensive diagnostic criteria exist but they necessitate allograft biopsies which in turn increases clinical risk and can pose certain logistical and economic problems in service delivery. Undermining these challenges further, are known problems with inter-observer interpretation of biopsies and uncertainty as to the long-term implications of milder or indeed asymptomatic episodes. Increased risk of chronic lung allograft dysfunction (CLAD) has long been considered the most significant consequence of ACR. Consensus is lacking as to whether this applies to mild ACR, with contradictory evidence available. Given these issues, research into alternative, minimal or non-invasive biomarkers represents the main focus of research in ACR. A number of potential markers have been proposed, but none to date have demonstrated adequate sensitivity and specificity to allow translation from bench to bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.